GenSight Biologics Announces 1 Year Safety data and Efficacy signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa

GenSight Biologics to Present at Upcoming 2022 Medical Conferences

GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment

BIO-Europe 2021, Virtual

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual

39th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), San Antonio, TX (USA)

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October

54th Annual Scientific Meeting of the Retina Society, Chicago (IL), USA